日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

AGS15E单药治疗转移性尿路上皮癌患者的安全性和药代动力学I期剂量递增研究

Petrylak, Daniel P; Eigl, Bernhard J; George, Saby; Heath, Elisabeth I; Hotte, Sebastien J; Chism, David D; Nabell, Lisle M; Picus, Joel; Cheng, Susanna Y; Appleman, Leonard J; Sonpavde, Guru P; Morgans, Alicia K; Pourhosseini, Pourya; Wu, Ruishan; Standley, Laura; Croitoru, Ruslan; Yu, Evan Y

Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer

帕尼单抗-IRDye800CW联合经口机器人手术治疗口咽癌患者的II期临床试验中期结果

Stone, Logan D; Kasten, Benjamin B; Rao, Shilpa; Gonzalez, Manuel L; Stevens, Todd M; Lin, Diana; Carroll, William; Greene, Benjamin; Moore, Lindsay S; Fuson, Andrew; James, Sherin; Hartman, Yolanda E; McCammon, Susan; Panuganti, Bharat; Nabell, Lisle M; Li, Yufeng; Li, Mei; Bailey, Luke; Rosenthal, Eben L; Jeyarajan, Harishanker; Thomas, Carissa M; Warram, Jason M

Traditional risk factors and cancer-related factors associated with cardiovascular disease risk in head and neck cancer patients

传统危险因素和癌症相关因素与头颈癌患者心血管疾病风险相关

Mukherjee, Amrita; Wiener, Howard W; Griffin, Russell L; Lenneman, Carrie; Chatterjee, Arka; Nabell, Lisle M; Lewis, Cora E; Shrestha, Sadeep

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

BRAF 和 MEK 抑制剂联合治疗广泛转移性 BRAF 突变型唾液导管癌的一线治疗

Lin, Victor T G; Nabell, Lisle M; Spencer, Sharon A; Carroll, William R; Harada, Shuko; Yang, Eddy S

Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies

甲状腺或环状软骨侵犯对采用器官保留策略治疗的喉癌或下咽癌患者的预后意义

Wagner, Marcus M; Curé, Joel K; Caudell, Jimmy J; Spencer, Sharon A; Nabell, Lisle M; Carroll, William R; Bonner, James A

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer

一项针对新诊断为雌激素受体或孕激素受体阳性乳腺癌的绝经后女性患者的术前(新辅助)来曲唑联合贝伐单抗的试点试验

Forero-Torres, Andres; Saleh, Mansoor N; Galleshaw, Janice A; Jones, Cheryl F; Shah, Jatin J; Percent, Ivor J; Nabell, Lisle M; Carpenter, John T; Falkson, Carla I; Krontiras, Helen; Urist, Marshall M; Bland, Kirby I; De Los Santos, Jennifer F; Meredith, Ruby F; Caterinicchia, Valerie; Bernreuter, Wanda K; O'Malley, Janis P; Li, Yufeng; LoBuglio, Albert F